Core Insights - The Diagnostics segment of Tempus AI (TEM) saw significant growth in 2025, primarily due to the increasing adoption of precision oncology testing and the integration of artificial intelligence with genomic diagnostics [1][10] - Minimal Residual Disease (MRD) testing emerged as one of the fastest-growing areas within Diagnostics, highlighting the rapid adoption of advanced monitoring technologies in cancer care [1][10] - Tempus' extensive clinical network, which includes over 5,500 hospitals and more than 8,500 regularly ordering oncologists, supports the strong performance of the diagnostics segment [1] Diagnostics Growth Factors - Tempus' multi-assay genomic testing platform, which includes advanced oncology tests such as xT, xR, xF, xH, and xE, has significantly contributed to the growth of the diagnostics segment [2] - The integration of artificial intelligence and multimodal data analysis into Tempus' diagnostic platform has been a major factor in advancing the diagnostics segment [2] - Innovative tools like Paige Predict, which analyzes digitized pathology slides to predict genetic mutations, and the Immune Profile Score, which refines traditional biomarkers, further enhance Tempus' diagnostic capabilities [3] Strategic Acquisitions - The acquisition of Ambry Genetics has strengthened Tempus' diagnostics segment by expanding its capabilities in hereditary cancer testing and broadening its overall sequencing portfolio [4] Industry Updates - Illumina (ILMN) is focusing on its core strengths in genomics, with the clinical market being a primary growth driver as sequencing adoption expands globally [5] - Illumina launched BioInsight, a new business aimed at providing comprehensive data solutions, with its first product, Billion Cell Atlas, attracting interest from biopharma partners [6] - Guardant Health (GH) made advancements in precision oncology and liquid biopsy testing, particularly with its Guardant360 liquid biopsy test and the expansion of its MRD testing platform, Guardant Reveal [7][8]

Illumina FY Conference Summary Company Overview - **Company**: Illumina (NasdaqGS:ILMN) - **Event**: FY Conference at TD Cowen Global Healthcare Conference - **Date**: March 03, 2026 Key Industry Insights - **Product Roadmap**: Illumina showcased its innovation strategy at the AGBT conference, emphasizing the NovaSeq X platform and its capabilities for both high and low capacity applications [4][5] - **TruPath Technology**: Launched as a library prep solution that eliminates traditional library preparation time, allowing for genome sequencing at a cost of $395, which is positioned as the lowest price for high-quality genome sequencing [6][7] - **Spatial Technology**: Illumina is advancing spatial technology to analyze larger tissue samples, which has generated significant customer interest [8][9] - **Competitive Landscape**: Illumina acknowledges competition from Roche, highlighting differences in workflow and pricing models, and expresses confidence in its ability to compete effectively [11][12] Financial Guidance - **Growth Projections**: For 2026, Illumina projects organic growth of 1%-3% excluding China, with a potential upside if the clinical business performs better than expected [30][31] - **Operating Margin**: Targeting a 150 basis point improvement in operating margin, aiming for a 26% operating margin in the near future [31][32] - **Earnings Per Share (EPS)**: Anticipating double-digit growth in EPS, despite headwinds from the SomaLogic acquisition [32] Market Dynamics - **Clinical vs. Research**: The clinical segment is expected to drive growth, particularly in oncology, with a shift towards minimal residual disease (MRD) detection and early cancer detection [43][44] - **Research Challenges**: The research segment faces ongoing pressures, but Illumina remains optimistic about maintaining high single-digit growth in a competitive environment [52] Product Innovations - **Q70 Scores**: Illumina plans to introduce Q70 scores for high sensitivity MRD applications within the next 18 months, which is expected to enhance clinical applications [5][58] - **Protein Prep**: The acquisition of SomaLogic is expected to expand Illumina's capabilities in protein analysis, with a focus on reducing costs and increasing the number of proteins analyzed [64][68] - **BioInsight**: A new initiative aimed at creating large datasets for AI model training in biology, which will be monetized through subscriptions to pharmaceutical companies [92][96] Competitive Positioning - **Roche Comparison**: Illumina believes it is well-positioned against Roche, particularly with the TruPath technology, which offers unique insights and a simpler workflow compared to Roche's offerings [100][101] - **Market Sentiment**: Illumina's leadership expresses confidence in its competitive edge, citing strong R&D and commercial teams as key advantages [108] Conclusion - **Future Outlook**: Illumina is committed to strong growth in a competitive landscape, with a focus on innovation and customer success in both clinical and research applications [108]

Financial Data and Key Metrics Changes - Illumina reported Q4 2025 revenue of $1.16 billion, a 5% increase year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, reflecting a 42% year-over-year growth [26] - Non-GAAP operating margin expanded to 23.7%, up 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% in Q4 2025, excluding China, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue reached $755 million, an 8% increase year-over-year [22] - Research and applied markets consumable sales were roughly flat year-over-year, indicating a stabilization compared to previous quarters [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting ongoing export restrictions [22] - Clinical market growth outside of China was 20%, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew over 30% year-over-year, primarily from clinical applications [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [11][12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [30][31] - Management highlighted the importance of adapting to the evolving funding environment in the research sector [44] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [7] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The company plans to continue share repurchases opportunistically, with $643 million remaining on its authorization [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth momentum [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various applications [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and highlighted ongoing discussions with customers regarding pricing and workflow efficiencies [74][76]

Financial Data and Key Metrics Changes - Illumina reported Q4 revenue of $1.16 billion, up 5% year-over-year on a reported basis and 4% on a constant currency basis [20][22] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [26] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [25] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [5][8] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with 11% growth excluding China [22] - Research and applied markets consumable sales were roughly flat year-over-year, reflecting ongoing uncertainty in the funding environment [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, representing a $25 million decline from Q4 of 2024 [22] - Clinical market maintained momentum, growing 20% outside of China, driven by broader adoption of NGS-based testing [22] - Total sequencing GB output grew at a rate of more than 30% year-over-year, primarily from clinical customers [24] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [10][13] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities for deeper biological insights [12] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in 2026 [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [17][30] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid-to-high single digits [30][31] - Management highlighted the importance of adapting to the evolving market dynamics and customer needs, particularly in the clinical space [16][70] Other Important Information - Illumina returned approximately $740 million to shareholders through share repurchases in 2025 [7] - The company ended Q4 with approximately $1.63 billion in cash and cash equivalents [28] - The acquisition of SomaLogic was completed for an upfront payment of $350 million, with potential royalties and milestone payments [27] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and discussed capital deployment priorities [36][38] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects a cautious approach, considering uncertainties in the research environment, but remains optimistic about clinical growth [42][45] Question: Instrumentation split between research and clinical - Management indicated that over 60% of NovaSeq X placements were to clinical customers, with expectations for this trend to continue [50][52] Question: Growth drivers in oncology and genetic applications - Management noted that oncology remains the main growth driver, with increasing use of genetic profiling for various diseases [66] Question: Competitive landscape and pricing strategies - Management expressed confidence in Illumina's competitive position and the ability to address market segments with different pricing strategies [74][76] Question: China market assumptions and BioInsight monetization - Management discussed ongoing conversations with Chinese regulators and the potential for growth in the BioInsight business, emphasizing its early-stage momentum [80][81]

Financial Data and Key Metrics Changes - In Q4 2025, Illumina's revenue reached $1.16 billion, reflecting a 5% year-over-year increase on a reported basis and a 4% increase on a constant currency basis [18][19] - Non-GAAP EPS for Q4 was $1.35, growing approximately 42% year-over-year, exceeding guidance [24] - Non-GAAP operating margin was 23.7% in Q4, expanding 400 basis points year-over-year [23] Business Line Data and Key Metrics Changes - Clinical consumables revenue grew 20% year-over-year in Q4, driven by increased adoption of sequencing-based diagnostic tests [4][19] - Sequencing consumables revenue was $755 million, up 8% year-over-year, with a notable 11% increase excluding China [19] - Sequencing instruments revenue was approximately flat year-over-year at $154 million, with strong placements of NovaSeq X [22] Market Data and Key Metrics Changes - Greater China revenue was $55 million, down $25 million from Q4 2024, reflecting export restrictions [19] - Clinical market outside China grew 20%, driven by broader adoption of NGS-based testing [19] - Research and applied markets saw consumable sales remain roughly flat year-over-year, indicating ongoing uncertainty in the funding environment [20] Company Strategy and Development Direction - Illumina's strategy focuses on three pillars: core sequencing, scaling multi-omics, and expanding service data and software capabilities [9][12] - The acquisition of SomaLogic is expected to enhance Illumina's position in the proteomics market, integrating capabilities to accelerate innovation [10][11] - The company aims to introduce new technologies, including spatial transcriptomics and constellation map read technology, in the first half of 2026 [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built in the second half of 2025, expecting organic revenue growth of 2%-4% in 2026, excluding China [15][27] - Clinical consumables are projected to grow double-digit to mid-teens in 2026, while research consumables are expected to decline mid- to high-single digits [15][29] - Management highlighted the importance of adapting to evolving market dynamics and customer needs, particularly in the context of multi-omics [14][78] Other Important Information - The company returned approximately $740 million to shareholders through share repurchases in 2025 [5] - Illumina ended Q4 with approximately $1.63 billion in cash and cash equivalents, maintaining a strong balance sheet [25] - The company plans to change geographical reporting segments starting in Q1 2026 to better align with its commercial structure [31] Q&A Session Summary Question: Operating margin guidance and capital deployment - Management confirmed that the guidance includes an assumption of ending the year at 26%-27% operating margin and remains committed to long-term margin targets despite the SomaLogic acquisition [33][36] Question: Clinical performance guidance for 2026 - Management explained that the guidance reflects continued momentum in clinical growth, with expectations for mid-teens growth, while acknowledging challenges in the research environment [40][42] Question: Instrumentation split between research and clinical - Over 60% of Q4 instrument placements were clinical, with expectations for this trend to continue into 2026 [46][48] Question: Growth drivers in oncology and genetic applications - Oncology is expected to remain the main growth driver, with significant uptake in genetic profiling for various diseases [62][64] Question: BioInsight monetization strategy - Management outlined plans for monetizing BioInsight through specialized data and subscription-based models, indicating a multi-year opportunity [78][79]

Core Insights - Illumina, Inc. (ILMN) is scheduled to announce its fourth-quarter 2025 results on February 5, with adjusted earnings per share (EPS) of $1.34 in the last reported quarter, exceeding the Zacks Consensus Estimate by 15.5% [1] Q4 Estimates - The Zacks Consensus Estimate for fourth-quarter revenues is $1.16 billion, indicating a 4.6% growth from the previous year [2] - The earnings estimate is $1.26 per share, reflecting a 46.5% increase from the year-ago figures [2] Estimate Revision Trend - Earnings estimates for the fourth quarter have risen by 2.4% to $1.26 over the past 30 days [3] Factors Influencing Q4 Performance - The Core Illumina segment's performance may be impacted by macroeconomic challenges, including the Russia-Ukraine conflict and reduced U.S. government funding for the NIH [4] - The company faces cost exposure related to imports from its Singapore manufacturing facility, while the Chinese Ministry of Commerce has lifted its export ban on Illumina's sequencing instruments, although the company remains on the Unreliable Entities List [4] Positive Developments - Illumina is expected to benefit from the momentum of the NovaSeq X in Q4, with high-throughput volumes likely increasing due to strong clinical market demand outside of China [5] - The company exceeded its goal of high-throughput gigabases shipped and revenues on the X platform, indicating strong demand for sequencing [6] Revenue Projections - Sequencing Consumables revenues are projected to grow by 3.2% year-over-year in Q4, despite ongoing funding uncertainty affecting research customers [7] - Sequencing Instruments revenues may decline by 12.2% year-over-year, impacted by export restrictions in Greater China [8] Strategic Initiatives - Illumina's strategic focus includes growing its core sequencing business, scaling into multiomics, and enhancing services and software capabilities [11] - The launch of the Illumina Protein Prep assay and the introduction of BioInsight are expected to positively influence Q4 revenues [12] Earnings Prediction - Illumina has an Earnings ESP of +2.25%, indicating a higher likelihood of beating estimates [13]

44th Annual J.P. Morgan Healthcare Conference Jacob Thaysen, PhD Chief Executive Officer January 13, 2026 © 2026 Illumina, Inc. All rights reserved. © 2026 Illumina, Inc. All rights reserved. Cautionary Notes On Forward Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: J.P. Morgan Healthc ...

Core Insights - Illumina reported Q3 2025 revenue of $1.084 billion, flat year-over-year, slightly above market expectations, with clinical applications driving growth outside of China [1][3] - The company raised its full-year earnings forecast to a range of $4.27 billion to $4.31 billion, an increase of $200 million from previous guidance [12][33] - Illumina's stock surged by 24.76% following the positive earnings report and upward revision of guidance, reversing a downward trend [1][3] Financial Performance - Total revenue: $1.084 billion (year-over-year flat, constant currency flat) [3] - Product revenue: $927 million, up 1.4% year-over-year [3] - Service and other revenue: $157 million, down 5.4% year-over-year [3] - GAAP operating margin: 21.0%, Non-GAAP operating margin: 24.5% [3] - GAAP net income: $150 million, Non-GAAP net income: $206 million [3] - Earnings per share (EPS): GAAP $0.98, Non-GAAP $1.34 [3] - Operating cash flow: $284 million, free cash flow: $253 million [3] - Share repurchase: 1.2 million shares for a total of $120 million at an average price of $97.10 [3] Product and Technology Developments - Illumina launched several new products and technologies, including the 5-base Solution, Constellation Mapped Read, BioInsight, TruSight Oncology Comprehensive, and Illumina Protein Prep [3][4] - The company is extending its strategy from genomic sequencing to multi-omics and proteomics [4] Market and Regulatory Dynamics - The Chinese market is still affected by export restrictions and the "unreliable entity list," but Illumina achieved growth in other regions [5][22] - The company is focused on optimizing global supply and cost structures to mitigate geopolitical risks [5] Detailed Performance Analysis - NovaSeq X platform showed strong performance with over 55 units installed in Q3, aligning with the target of 50 to 60 units per quarter [15][19] - Approximately 78% of testing samples and 51% of revenue were generated through the X platform, indicating a rising conversion rate from NovaSeq 6000 to NovaSeq X [18][25] - Clinical market revenue from sequencing consumables grew at a double-digit rate year-over-year [20] Future Strategy - Illumina's strategic direction includes developing core sequencing business, accelerating X platform transition, and expanding multi-omics [28] - The company has made significant progress in these areas, including the launch of the Illumina Protein Prep product and the establishment of BioInsight for genomic data applications [31][32]

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 was reported at $1.08 billion, reflecting a year-over-year growth of approximately 2% excluding China, and was above the guidance range [6][18] - Non-GAAP operating margin expanded by 190 basis points to 24.5%, and non-GAAP diluted EPS increased to $1.34, representing an 18% year-over-year growth [18][24] - Greater China revenue was $52 million, with overall revenue growth outside of China being a significant milestone [18][25] Business Line Data and Key Metrics Changes - Sequencing consumables revenue was $747 million, roughly flat year-over-year, but up about 3% excluding China [18][22] - Clinical business saw double-digit revenue growth outside of China, driven by comprehensive genomic profiling and sequencing-intensive applications [18][22] - Research consumable sales declined by high single digits outside of China due to funding uncertainty and pricing dynamics [18][22] Market Data and Key Metrics Changes - The transition to the NovaSeq X platform progressed significantly, with approximately 78% of volumes and 51% of revenue in Q3 being sequenced on X [19][20] - Total sequencing GB output on connected high and mid-throughput instruments grew at a rate of more than 30% year-over-year, primarily driven by clinical demand [21] - The instruments business in Greater China experienced a decline of approximately 54% due to export restrictions [22] Company Strategy and Development Direction - The company is focusing on three strategic pillars: growing the core sequencing business, scaling into multi-omics, and expanding services, data, and software capabilities [9][12] - The launch of Illumina Protein Prep and the five-base solution are part of the strategy to enhance multi-omics capabilities [11][12] - The company aims to achieve high single-digit revenue growth and 20% non-GAAP operating margins by 2027, excluding Greater China [16][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the clinical business as the primary driver of revenue growth, with expectations for a gradual return to growth in the research segment [15][16] - The company remains cautious about the regulatory environment in China but is encouraged by the resilience shown in that market [31] - Management highlighted the importance of customer feedback in shaping future product offerings and maintaining competitive advantage [14][45] Other Important Information - The company has increased its revenue guidance for Greater China by $20 million to approximately $220 million for the year [25] - Non-GAAP operating margin guidance has been raised by approximately 60 basis points to a range of 22.75% to 23% [26] - The company ended the quarter with approximately $1.28 billion in cash and cash equivalents, with plans for continued share repurchases [24] Q&A Session Summary Question: Insights on China and 2026 outlook - Management is pleased with performance in China despite unresolved regulatory issues and is optimistic about customer relationships [30][31] Question: 2026 revenue growth framework - Management acknowledges the potential for low single-digit revenue growth in 2026, driven by clinical growth and muted research revenue [32][34] Question: Margin outlook and operational efficiency - Management is confident in further margin expansion due to disciplined cost management and operational improvements [33][35] Question: Consumables growth and market dynamics - The growth in consumables was primarily driven by clinical demand, with no significant pull forward from academic or government segments [37][38] Question: Competitive landscape and market pressures - Management views competition positively, emphasizing Illumina's multi-dimensional value proposition over single-dimensional competition [44][45] Question: Future instrument placements and market trends - Management expects stable instrument placements moving forward, supported by ongoing demand in clinical and research applications [46][47] Question: Research market dynamics and funding predictability - Management notes that predictability in grant funding is crucial for research spending, with ongoing monitoring of the funding environment [60]

Financial Performance - Illumina's Q3 2025 revenue was $1.08 billion, approximately flat year-over-year in constant currency and reported terms[8] - Non-GAAP operating margin was 24.5%[8] - Non-GAAP diluted EPS reached $1.34, an 18% increase[8, 31] - Free cash flow for Q3 2025 was $253 million[33, 34, 35] Revenue Breakdown - Sequencing consumables revenue was $747 million, a 1% increase[16] - Sequencing instruments revenue was $107 million, a 3% increase[28] - Sequencing service and other revenue was $147 million, a 2% decrease[28] - Revenue excluding Greater China grew by approximately 2% year-over-year in constant currency[8] Regional Performance - Americas revenue was $612 million, a 1% increase[8] - Europe revenue was $309 million, a 6% increase[8] - AMEA (Asia Pacific, Middle East and Africa) revenue was $111 million, a 6% increase[8] - Greater China revenue was $52 million, a 31% decrease[8] NovaSeq X Transition - Over 50% of high-throughput revenue was attributed to NovaSeq X[8, 13, 21] - Over 75% of high-throughput gigabases shipped were attributed to NovaSeq X[13, 21] FY25 Guidance - Illumina anticipates full year 2025 revenue growth between 0% and 1% for the rest of the world and between -1.5% and -0.5% for Greater China[37] - The company projects full year revenue between $427 billion and $431 billion[37]